We examined the prevalence of use and cost impact of DPP-4 inhibitors and GLP-1 receptor agonists in people with diabetes.
Frederick Brown, PharmD
Advertisement
Articles by Frederick Brown, PharmD
Based on American College of Rheumatology recommendations and novel emerging treatment options, the trend of increasing biologic use for rheumatoid arthritis is expected to continue.
Advertisement
Latest Updated Articles
- Conventional and Biologic Rheumatoid Arthritis Therapies: Utilization and Cost Trends
Published: December 12th 2012 | Updated:
- The Expanding Role of New Medications in the Treatment of Type 2 Diabetes Mellitus
Published: August 21st 2013 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Pharmacists Can Drive Equitable Diagnostics Access, Improve Antimicrobial Resistance Stewardship
2
From Stigma to Breakthrough: Psychedelic Medicine
3
CHEST 2025: Brensocatib Shows Potential to Slow Structural Lung Changes in Bronchiectasis
4
How Pharmacy and Public Health Partner to Combat Infectious Diseases
5
